MedTrace Logo

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

NCT06410924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2026-05-01

No results posted yet for this study

Summary

This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).

Conditions

  • NAFLD
  • NASH

Interventions

DRUG

DD01

Dual GLP-1 and glucagon receptor agonist

DRUG

Placebo

Placebo matching DD01

Sponsors & Collaborators

  • Neuraly, Inc.

    lead INDUSTRY

Principal Investigators

  • Dennis To · Neuraly, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2025-05-20
Completion
2026-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410924 on ClinicalTrials.gov